The company’s stock climbed 9.4% to $269.38 in recent trading, partially offsetting a year-to-date decline of 5.2%. This rally follows a quarterly report where Insulet posted net income of $101.6 million, or $1.44 per share, compared to $100.7 million in the prior year. On an adjusted basis, earnings reached $1.55 per share, comfortably exceeding the $1.46 per share forecasted by analysts, according to data from FactSet.

Revenue Growth and 2026 Outlook

Revenue for the period surged 31% to $783.8 million, surpassing the $769 million anticipated by the market. This growth reflects sustained demand for the company’s tubeless insulin pump systems. Looking ahead, Insulet provided an optimistic outlook for its mid-term performance, suggesting that the current momentum in the diabetes care sector will persist through the next two fiscal years.

The company’s guidance for 2026 outlines a path for aggressive expansion and margin improvement, according to the report:

• Revenue growth projected between 20% and 22%.
• Adjusted earnings per share growth expected to exceed 25%.
• Continued scaling of flagship product lines to meet global demand.